The results showed that anti-CD22 CAR-T cells can mediate similar potent antineoplastic effects to anti-CD19 CAR-T cells in pre-B ALL patients, and they also exhibit great efficacy in anti-CD19 immunotherapy-resistant patients with loss of or diminished surface expression of CD19 [50,51], indicating that CD markers are extremely important targets (biomarkers) for targeted therapy to eradicate hematologic malignancies. Here, CD19 is linked to hematologic disorder.